Meeting
2023 ASCO Genitourinary Cancers Symposium
The impact of genomic biomarkers on a validated clinical risk prediction model for upgrading/upstaging among men with low-risk prostate cancer.
Authors
Avery Braun
University of California, San Francisco (San Francisco, CA), San Francisco, CA
Avery Braun , Janet E. Cowan , June M. Chan , John Neuhaus , Peter Carroll , Matthew R. Cooperberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 262)
DOI
10.1200/JCO.2023.41.6_suppl.262
Abstract #
262
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.
First Author: Eric Margolis
Poster
2024 ASCO Genitourinary Cancers Symposium
The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI, and targeted biopsies: Real-world evidence from 2018 to 2022.
First Author: Thorgerdur Palsdottir
Poster
2022 ASCO Genitourinary Cancers Symposium
Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.
First Author: Daniel Eidelberg Spratt
Poster
2019 Genitourinary Cancers Symposium
Molecular characterization of longitudinally tracked prostate cancer foci in men on active surveillance for low risk disease.
First Author: Jeffrey J. Tosoian